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ABSTRACT 
ALCOHOL BIOMARKERS AS PREDICTIVE FACTORS OF REARREST IN 
HIGH RISK REPEAT OFFENSE DRUNK DRIVERS 
 
by 
Brian Kay 
 
The University of Wisconsin- Milwaukee, 2013 
Under the Supervision of Professor Rohit Kate 
 
Alcohol biomarkers, or naturally occurring molecules which occur in 
response to one’s alcohol consumption, are proving to be a value tool in 
objectively monitoring one’s alcohol consumption. Coupling this assessment tool, 
with advances in computing power, new and powerful predictions are becoming 
evermore possible. In this retrospective study, data was first collected that 
consisted of a sample of 249 drivers convicted of driving under the influence 
charge and who monitored over the course of a year by biomarker blood tests. 
This data was then analyzed using machine learning methods. TwoStep cluster 
analysis showed distinct drinking groups within the drivers who were monitored. 
In addition to this, a cost sensitive learning classifier was utilized in order to 
predict if a driver would relapse, having a subsequent driving under the influence 
arrest. The algorithm was able to predict 64% of the cases within the training set. 
Additionally, learning curves indicated that correctly classified cases increased 
with the increase of training data, indicating that predictions may become more 
accurate with the availability of more training data.  
Keywords: alcohol, biomarkers, recidivism 
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Introduction 
 
Alcohol biomarkers are naturally occurring molecules which develop in 
response to the ingestion of alcohol.  These molecules are proving to be an 
invaluable tool to objectively monitor the alcohol consumption for those deemed 
to be at a high risk of re-arrest for driving while intoxicated. This assessment tool 
combined with advances in computing power will allow for new and more 
powerful predictions in the future. 
A survey released in 2009, by the United States Department of Health and 
Human Services, highlighted current rates of Driving While Under the Influence 
(DUI) and measured the way in which drunk driving is perceived by the survey 
participants.  In the aforementioned article, twenty-six percent of Wisconsin 
adults stated that they had driven while intoxicated within the last year 
(SAMSHA, 2007).  This reflects the highest occurrence of people driving while 
under the influence in the country; ranking Wisconsin as having the highest 
prevalence of drunk driving in the country.   
In response to this study and in an effort to stop people from driving while 
intoxicated, preventative measures have been put into place to protect the public.  
These include an increased police presence throughout the community and 
various ad campaigns run through local media. While these interventions are 
designed to avert potential first time offenders; those deemed to be chronic 
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offenders present quite a different set of problems and challenges for treatment 
teams and increasing rates of recidivism. 
 
1.1 Current approaches to reduce recidivism   
Indeed it is clear that little has been done to prevent chronic offenders from 
endangering the public. Research has found that collision rates of these 
individuals are twice as high as the general population (Korzec, Bär, Koeter, & 
Kieviet, 2001).  Drivers that have been convicted of more than three offenses 
are commonly classified as high-risk reoffenders or “hardcore drunk drivers.”  It 
is this specific population that presents two interesting challenges to both public 
law makers and alcohol assessment facilities.  On one hand, assessment 
facilities are challenged with creating programs specifically designed to target  
repeat offenders; while on-the-other, community law makers must decide  
whether to increase penalties for those that continue to drive while intoxicated.  
  The well-being of the general population is put into jeopardy due to the 
specific “risks” this subgroup of drivers are willing to take.  Measures must be 
taken to protect the public, as well as the “hardcore” offender.  Research is 
finding that there are distinct causes of increased recidivism among those 
classified within this population. However, Alcohol Use Disorder appears to be 
one of the largest contributing factors (Couture, Brown, Tremblay, Kin, Ouimet, 
& Nadeau, 2012).  
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The assessment of Alcohol Use disorder has posed to be a difficult process 
through traditional methods. Research has proven that methods of alcohol 
consumption recall have been biased, where the majority of the bias is due to an 
individual underreporting or over reporting (Bean, Roska, Harasymiw, Pearson, 
Kay, & Louks, 2009).  In many cases, the individual will underreport their use in 
an effort to guide treatment to their preference.  As a result of these factors, new 
and novel approaches to curb the rising rates of recidivism as well as aides to 
more effectively diagnose Alcohol Use Disorder have been developed.   
In Wisconsin, once the individual has been cited for driving under the 
influence, he/she can be referred to a state run assessment facility. The 
individual’s alcohol and drug use will be assessed through an in-person 
interview.  Based on the result of this assessment a driver’s safety plan, or 
treatment protocol can then be established, whereby the person will be required 
to seek appropriate modalities of treatment.  
 
1.2 Interlock Devices  
One method to curb repeat offenders is the use of an interlock system. An 
interlock system is a device, when installed in a car, requires the driver to blow 
into a breathalyzer before the car can be started. If the interlock system detects 
that the driver has been drinking it will not allow the car to be started. 
 The first commercial interlocks, utilizing breathalyzers, were developed in 
the 1970’s, however it was found that this system did not work particularly well 
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(Elder, et al., 2011). It was not until the 1990’s that interlock systems became 
more widespread, effective, and ultimately more usable. With the advent of these 
“ second generation” systems the National Highway Traffic Safety Administration 
began to fold them into individual drivers safety plans.  
 Today, it is estimated that 1.4 million drivers in the United States have an 
interlock system in their automobile (Elder, et al., 2011). However, this 
represents a small population in the United States and measures are being 
implemented in order to make interlocks more available. Based on the research 
of Elder (2011), it has been found that the interlocks utilized today are used in 
specific populations that are at a higher risk of offending, and those individuals 
that were offered the use of an interlock system to receive a reduced sentence. 
 An analysis of the data, for those drunk drivers likely to re-offend, 
discovered that the use of interlocks,“ Substantially, lower[s] the risk for 
recidivism than those who have had their licenses suspended either after being 
deemed ineligible for an interlock or deciding not to have one installed.” (Elder, et 
al., 2011). Additionally, one study found that 93% of individuals who were 
deemed eligible for installing an interlocked had it done (Voas, Tippets , Fisher, & 
Grosz, 2010).  
However, interlocks have a multitude of problems, which hamper their 
ability to become a widespread solution to curb drunk driving. Unfortunately, 
interlock devices are typically expensive to install and maintain. In the state of 
Wisconsin the cost of an interlock device can typically cost between $75-$150  to 
install;$60-$90 for monthly maintenance, leasing fees and removal fees which 
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can cost from $40-$60 (Wisconsin Department of Transportation, 2010). These 
devices require the offender to present to a specified facility in order for the 
device to be installed. Unfortunately, the devices are easily cheated.  For 
example, an intoxicated driver can have a non-intoxicated passenger blow into 
the device in order to start the vehicle. Furthermore limited effectiveness rates 
have not been established on this treatment intervention.  
 
1.3 Alcohol Biomarkers  
Biological based indicators are also being utilized in the state of Wisconsin 
to monitor repeat offense drunk drivers. One of these approaches is monitoring 
high-risk subjects through the use of biomarker monitoring. A biomarker is,  
“ A biological indicator that develops in the body when the person 
consumes alcohol, and stays elevated for longs periods of time- weeks, 
even months – after the person has stopped drinking” (Walker, 2012). 
Biomarkers have been utilized in Europe for close to 30 years to monitor 
drivers who have been convicted of driving under the influence (Appenzeller, 
Schneider, Maul, & Wennig, 2005). This pioneering model monitors drunk drivers 
once they have been convicted, for a period of one year. During this time, if a 
biomarker result is positive then the driver will lose his/her driver’s license 
indefinitely. If the driver successfully goes through this time without a positive 
biomarker then their driver’s license will be reissued (Couture, Brown, Tremblay, 
Kin, Ouimet, & Nadeau, 2012). The increased level of monitoring allows the 
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driver to have proper allocation of resources for addressing their struggles with 
alcohol. If the biomarker shows that the individual’s alcohol consumption is 
elevating, other interventions can be implemented in order to reduce this 
behavior. 
1.4 Commonly Used Biomarkers 
Currently, there are two general categories of alcohol biomarkers, those, 
which directly measure a derivative of the ethanol molecule in the body (direct), 
and those that measure the toxic effects of alcohol on one’s system (indirect). 
The following include some of the biomarkers  that are commonly used in the 
state of Wisconsin and also some that are used in the European model: 
Carbohydrate-deficient Transferrin (CDT) 
The gold standard in indirect biomarkers is Carbohydrate-deficient 
Transferrin (CDT). This molecule is a derivative of glycoprotein transferrin, which 
is the main molecule that carries iron in the body’s bloodstream. When an 
individual consumes over 60g of alcohol per day, for over 2 weeks the body 
produces the Carbohydrate-deficient version on the molecule. CDT produces a 
high diagnostic specificity (The ability to indicate the absence of a CDT in a 
“truly” negative sample) for heavy alcohol use. Javors and Johnson (1998) 
established this rate at 93%.  In addition, low incidences of false positives have 
been established due to CDT being highly specific to alcohol consumption 
(Peterson, 2004/2005). With the high specificity as well as low instances of false 
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positives, CDT proves to be an excellent marker if one is chronically heavy 
drinking.  
Serum Gamma-Glutamyl Transferase (GGT) 
The indirect molecule of Serum Gamma-Glutamyl Transferase (GGT) is a 
measure of liver function in the body. Physiologically, GGT is elevated when an 
individual consumes greater than 40g of alcohol per day for those deemed 
chronic alcoholics and 60g of alcohol per day in previous non-chronic alcoholics. 
GGT has varied sensitivity from 60 to 90%, documented in the research of 
Behrens et. al 1988.  GGT has varied specificity, which is documented in the 
range of 55% to 100% (Sharpe, 2001). 
GGT has a relatively long duration in the body, it remains detectable 14 to 
26 days after one stops drinking and ceases to be elevated after 4-5 weeks. 
Unfortunately, GGT levels can be influenced by other illegal substances as well 
as legal drugs. Physiological disorders such as, obesity, diabetes, and clotting 
disorders can also influences levels of GGT in one’s body (Rosman & Lieber, 
1990).  
Early Detection of Alcohol Consumption (EDAC) 
The Early Detection of Alcohol Consumption test is a statistical analysis of 
multiple routine lab tests designed to detect high levels of alcohol consumption in 
the body.  Utilizing Linear Discriminant Function, the EDAC produces a 
probability if an individual is regarded as a heavy drinker or an at-risk drinker. 
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The differentiation between these two types of drinkers allows clinicians to 
ascribe appropriate resources to the individuals.  
In a general population the EDAC performed marginally, producing 30% 
sensitivity in males and 42% sensitivity in females.  However, the EDAC excelled 
in regards to specificity, producing 96% in males and 90% females (Harasymiw, 
Vinson, & Bean, 2000).  
1.6 Prediction through biomarkers 
The objective monitoring of alcohol through the use of biomarkers is 
opening the door for sophisticated analytics to predict human behavior.  The 
concept of data mining, or the process of discovering unseen patterns or 
relationships within preexisting data has seen a proliferation with the increase in 
the amount of data collected as well as advances in computing power (Han, 
Kamber, & Pei, 2006). Powerful techniques in partnership with new objective 
techniques of monitoring behavior, is providing tremendous advances in 
predicting human behavior. The data collected from biomarker interventions, 
coupled with new patterns in previously collected data are revealing those at a 
high risk of reoffending. Also, these offenders can be classified and studied in 
order to ascribe the most appropriate interventions. Moreover, by identifying 
drivers who might be more likely to reoffend or relapse within their driver’s safety 
plan, clinicians can assign more treatment interventions in an effort to optimize 
outcomes.  
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Methods 
2.1 Waukesha County Biomarker Pilot 
In 2007 and continuing through 2009, The Addiction Resource Council of 
Waukesha County was the sole site for a pilot study using biomarkers.  This 
study monitored those deemed as high offense drunk drivers for a period of one 
year.  After a driver had committed a third drunk driving offense they were then 
assessed through this facility and later notified that they would be monitored 
through biomarkers via the Addiction Resource Council.  
 During the course of the one year monitoring period, clients were required 
to report to a local laboratory every three months for a blood sample to be 
collected. The blood sample would detect the presence of GGT, CDT, as well as 
EDAC levels, the results would be forwarded to the client’s assessor. The 
assessor would then be able to provide the appropriate interventions based on 
the levels of these biomarkers and subsequently guide the client’s driver’s safety 
plan.  
At the time of initial assessment, the client is required to sign a non-
disclosure agreement which served to release the results of the their biomarkers 
to the Addiction Resource Council, and to their physician if medical necessity 
indicated intervention (Appendix B). 
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The client completes a routine assessment to assess the severity of 
alcohol and drug use in the client. Based on the findings of the assessment, 
additional treatment was recommended in conjunction with being monitored by 
biomarkers. The combination of treatment as well as biomarker monitoring 
became the driver’s safety plan. In order for the client to successfully complete 
their driver’s safety plan, they would need to adhere to all four biomarker tests as 
well as adjunctive treatment recommendations. Upon successful completion, the 
client’s driver’s license would be reissued. However, if the client did not adhere to 
their drivers safety plan, the client could have their driver’s license revoked 
indefinitely.  
After completing their assessment, the client presented to their local lab 
facility in order to have their blood drawn, which would be analyzed for the 
presence of CDT, the assessment of the GGT levels as well as their EDAC 
result.  In addition to these biomarkers, demographic information on the client 
was collected including, age, gender, days between arrest and assessment (3rd 
offense), a binary marker if the client committed another re-arrest, employment 
status, marital status, and timeline follow-back information.  
At the time of the initial assessment the Timeline Follow Back (TLFB) was 
collected as well. The TLFB is an assessment which utilizes a calendar in order 
to establish the amount of days which an individual consumed alcohol within the 
past 30 days (Sobell, et. al. 1979). The client is asked to estimate how many 
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drinks of alcohol that they consumed per day. From this, the TLFB method 
establishes days drinking, days abstinent, as well as average drinks per day.  
As previously stated, the client would present to their local laboratory in 
order for a blood sample to be obtained for one year. The data would be inputted 
into a centralized database, where the lab values were recorded as well as the 
client’s demographic information.  
 
2.2 Waukesha Biomarker Dataset 
Permission was obtained from the Executive Director of the Addiction 
Resource Council in order to use the data produced from the pilot (Appendix A). 
The data was de-identified by the Addiction Resource Council, and given to this 
researcher via encrypted file. The dataset contained the 249 drivers who 
participated in this pilot project.  
The dataset contained the following variables: days between arrest and 
assessment, DUI offense number, age, marital status, employment status, initial 
timeline follow back information, as well as the EDAC, CDT, and GGT results for 
the client. In 2010, clients were classified as either those who had reoffended (a 
subsequent DUI in 2011) or no-re-offense based on information obtained by the 
department of transportation. This binary outcome was coupled with the client’s 
information and was included in this dataset.  
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In addition to obtaining permission by the Addiction Resource Council, the 
study protocol was reviewed by the Institutional Review Board at the University of 
Wisconsin- Milwaukee. The study received a Category 4 exempt status and was 
approved by IRB# 13.429 (Appendix C). 
The data was cleaned and transformed including identification of outliers, 
as well as identification of missing data.  Missing data was coded with a “?” in 
order to maintain integrity of missing cases.  
The data was split into two separate yet similar files in order to evaluate 
the efficacy of predictions based on how the biomarkers were classified. The 
biomarker data in file one was kept in continuous form, with the models 
predicting the target, “re-offense”, based on the raw scores from the biomarker 
results. Biomarker data in file two was transformed into binary values, either the 
client scored “Positive” or “Negative” based on their biomarker score and the 
target was again, the binary re-offense or no re-offense variable. The files were 
both converted into the “ARFF” format. The data was then analyzed using 
WEKA, an open source software for data mining and machine learning (Hall, 
Frank, Holmes, Pfahringer, Reutemann, & Witten, 2009). 
In the case for file 2, the following cut-offs were used in order to 
differentiate positive and negative results: 
CDT: Greater than 2.2% (Arndt, 2001) 
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GGT: Greater than 60 units per liter (U/L) (Bianchi , Ivaldi , Raspagni , 
Arfini , & Vidali , 2010) 
EDAC-Test: Greater that 40% (Harasymiw & Bean, 2001) 
 
Objectives 
3.1 Objectives for Biomarker Prediction and Clustering 
There were two primary objectives within the study, the first was to identify the 
drinking patterns within the existing biomarker data; and the second, was to 
predict which individuals were more likely to reoffend, and commit their 4th 
offense.  
1. Identifying drinking patterns 
Identify drinking patterns/ treatment patterns within the collected 
biomarker data. Clients were measured at four distinct points throughout their 
driver’s safety program. At all of these points, CDT, GGT, and EDAC information 
was collected. These values are distinct in every client. However, it is possible 
that distinct patterns of drinking were present within groups of clients. For 
example, a client who was previously a heavy drinker may have abstained upon 
commencement of his/her driver’s safety program. The values also may reflect a 
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high positive at the initial biomarker collection, and negative values at 
subsequent tests.  
2. Predicting Re-arrest in a high offense population  
Utilizing re-arrest data, which will be embedded within the provided 
dataset by the Addiction Resource Council, analyze predictive factors for the 
subsequent re-arrest (i.e. Identified drinking pattern, demographics, and 
biomarker data). This data will highlight a subset of individuals who may be 
inclined to a further re-arrest. These individuals may have non-compliance within 
the driver’s safety plan, or have continued to consume large amounts of alcohol 
through the driver’s safety plan.  
 
Results 
4.1 Group Demographics 
The data contained within the file produced an unbalanced dataset, in 
regards to the binary variable of “re-offense”, producing 36 “reoffenders” and 212 
“ No-Reoffenders.”  Additionally, the group was 86% male. Of the individuals 
within the dataset 68% were employed fulltime at assessment, and were 49% 
single. These groups fall into very distinct clusters, figure 4.1 illustrates the 
stratification of these clusters. Within the figure, the longer the horizontal bar the 
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more instances of the combination of the demographic which occurs. For 
example, single and full time individuals are the most populous combination.  
 
Figure 4.1 Distributions of employment status versus marital statues at 
assessment 
In predicting re-arrest, the target was the binary value, “ Re-offended” or 
“No Re-offense”. The following inputs were utilized in order predict this value, 
EDAC values baseline, 3-month,6-month, and final; GGT values baseline, 3-
month,6-month, and final; CDT values baseline, 3-month,6-month, and final, 
days between assess and arrest, timeline follow-back if they self reported 
abstaining or relapsing, age, martial status, and employment status at the time of 
arrest.  
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Figure 4.2 Distribution of individuals who reoffended and had no further re-
offense 
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Distribution of age at time of assessment: 
 
Figure 4.3 Distribution of age at time of assessment 
 
4.2 Predicting Re-arrest 
Due to the unbalanced dataset, cost sensitive versions of the classifiers 
were used which are available in WEKA as the Cost Sensitive Classifier under its  
meta classifiers.  A cost sensitive classifier analyzes the dataset in order to find a 
predicting  scheme that produces the least amount (cost) of errors. A cost matrix 
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tells  the classifier how to weight different types of misclassifications. The matrix 
below shows the penalizations  in a 6:1 ratio used in the experiments which is 
same as the ratio between “reoffenders” and “no-reoffense”:  
 
 A B 
No-Re-offense 0.0 1.0 
Reoffended 6.0 0.0 
Table 4.1 Matrix for penalizations of cost sensitive learning classifier 
It means that the penalty of a reoffended misclassified as no-re-offense is 
six times than the penalty of a no-re-offense misclassified as reoffended when 
the classifier is being trained. Several available base classifiers were tried for the 
cost sensitive learning classifier, these classifiers were evaluated by how many 
“re-offenses” the classifier was able to predict based on the dataset. The various 
classifiers which were tested and their associated predictive power can be found 
in (Appendix D).  
Support Vector Machine classifier was found to produce the highest 
amount of correct “Re-offense” predictions. Support Vector Machine classifiers, is 
a supervised learning model, which recognizes patterns within data. The 
classifier then predicts two possible outcomes based on the associated training 
data (Cristianini & Shawe-Taylor, 2000). The basic algorithm is based on a non-
probabilistic binary linear classification. However,  the algorithm can also do non-
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linear classification by using non-linear kernels, one of them being the Gaussian 
Kernel (Press, Teukolsky, Vetterling, & Flannery, 2007) which was found to work 
best in this study.  In this research, the support vector machine classifier 
analyzes the data and determines if a data point would match either a “Re-
offender” or “No Re-Offense”. Within WEKA, the support vector machine 
classifier utilized Single Minimal Optimization (SMO option in WEKA) numerical 
method technique. Normalization is important when running these classifiers. 
The data was automatically normalized before training with the algorithm.  
 The best results were produced in the file which utilized continuous 
biomarker data. The classifier was able to accurately predict 64% of the cases 
based on the aforementioned Support Vector Machine algorithm and using 10-
fold cross-validation. In this the data is split into 10 equal parts. Nine parts are 
used for training and then the trained classifier is tested on the tenth part. This is 
repeated 10 times with a different test set every time. The results of all the 10 
evaluations are then combined and reported.  The Support Machine Vector 
weighted the individual variables; these weights are illustrated in Appendix E. 
The confusion matrix for prediction utilizing a cost sensitive learning classifier as 
well as sequential minimal-optimization algorithm was: 
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Table 4.2 Confusion matrix for Cost sensitive learning classifier with SMO base 
classifier  
4.3 Evaluating the accuracy of the prediction  
The qualities of the predictions were evaluated based on percentage 
predicted correct by the confusion matrix. For example, when predicting the re-
offended category, the follow equation was utilized based the confusion matrix in 
figure 4.2: 
“B” /total Reffendorsx100= Percent of re-offenders correctly predicted by the cost 
sensitive classifier.  
(23/36) x 100= 64% 
In addition to this, the classifier misclassified the No-Reoffense individuals as 
well. “B”/total No-reoffense x 100. 
(117/213) x 100=54% 
This researcher also sought to evaluate if more data added will increase the 
percentage of correctly classified cases. Using the experimental setting within 
A B <-- classified as 
96 117 A=No-Re-offense 
13 23 B=Re-offended 
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WEKA this researcher utilized an Instances Results Listener which allows WEKA 
to vary the amount of training data which each analysis would use. The amount 
of training data in each analysis was partitioned by percentage : 90, 80, 70, 60, 
50, 40, 30, 10. In each partition of the training data, WEKA would utilize the same 
Support Vector Machine classifier as employed within the previous analysis. 
Figure 4.4 illustrates the percentages correctly classified by percentage of 
training data.  
 
Figure 4.4 Percentage classified correctly  
4.4 Value of the predictive input 
In addition to this, there were no specific biomarkers which predicted the 
re-arrest value better then others, with only slightly more importance of the final 
GGT value.  The importance of the biomarker values are visualized below, with 
the biomarker labeled (EDAC, GGT, or CDT) with the subsequent time period 
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illustrated (1,2,3, or 4). Figure 4.5 outlines if there were any correlation between 
the input variables and how important they were to the overall prediction. In the 
figure, a 1.0 would indicate a great importance to the accuracy of the prediction. 
Where a 0.0 would indicate no importance of influence to the prediction.  
 
Figure 4.5 Prediction input performance  
 
4.5 Clustering individuals throughout the course of 
monitoring 
Biomarker data was processed in order to produce a binary value, “ 
positive” or “Negative” as set by the aforementioned cut off’s. This data was then 
clustered utilizing a TwoStep clustering algorithm (IBM Corporation, 2011). The 
TwoStep cluster analysis, develops a Cluster Features Tree in order establish 
baseline nodes. These base lining nodes serve as a summary of the data. After 
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the tree has been formed, agglomerative clustering is performed in order to 
produce multiple solutions of the clusters. Agglomerative clustering  
 This researcher evaluated the cluster based on the silhouette coefficient 
which illustrates the cohesion of the cluster as well as the separation of the 
cluster (Kent University ). In addition to measuring the clusters as a whole, the 
silhouette value takes into account the cohesion and separation in the individual 
data points. The silhouette coefficient value produced was .814 which indicates 
good separation and tightness of the values. 
The cluster assignments are visualized in Figure 4.6. The figure illustrates 
foremost, the sizes of the clusters. Within the data there are 4 distinct clusters 
which each roughly make up 25% of the total data. Below is the size and how 
each input influences the predictor importance of the cluster. In descending 
order, are the importance of the predictor to the individual clusters with the 
classification of the predictor, as well as the percentage of individuals who scored 
that value within the cluster. For example, in cluster 1, 90.9% of individuals had a 
negative 4th EDAC. This value demonstrates the largest predictor in the formation 
of the cluster.  
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Figure 4.6 Biomarker cluster analysis  
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Discussion 
5.1 Applications of results 
 
 The results of data mining the dataset appear to indicate that there are 
defined groups of drinkers within the individuals who were monitored by 
biomarkers.  The importance of the inputs indicates that in all clusters the final 
EDAC was missing. Additionally, there were not enough positive biomarkers 
which warranted a defined cluster. However, there was enough missing data 
which warranted a defined cluster.  
By having defined groups of drinkers multiple treatment modalities can be 
established in response to these categories. Drivers who are more inclined to 
consume alcohol within their drivers safety plan can be allocated more resources 
or a more intensive drivers safety plan. Having access to this knowledge can also 
aid in assessors to ascribing the most appropriate treatment as well as 
evaluating their decisions when terminating an individual’s driver’s safety plan. 
 
5.2 Limitations of the data  
 There are also multiple limitations to the study. First, indirect biomarkers 
may produce inaccurate results. The biomarkers as stated before have multiple 
limitations based on substances or ailments that may produce false positives or 
false negatives. Prediction, hinges on the assumptions as well as the validity of 
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the inputted values, if there are inaccuracies within these values, the accuracy 
and precision of the prediction may come into question.  
However, new alcohol biomarkers are in the process of development, 
which accurately measure alcohol consumption with extremely low false 
negatives as well as false positive. These new direct biomarkers are inundating 
the market and new data is being collected with them as the primary measure. 
By utilizing these biomarkers in further studies, the inputs can be further verified 
and subsequently, more accurate predictions can be produced.  
Additionally, within the study there was variation between each of the 
clients testing phases. On average, there was 3 months between when they were 
scheduled to be tested and when they were actually tested. The variation in this 
time may not be detrimental, as the test covers a three month drinking history, 
however this variation may lead to non-accurate predictions. When speaking to 
members, of the addiction resource council regarding these variations, they 
stated that this was primarily due to clients missing their appointments due to a 
variety of reasons. Many times, the assessors I spoke to felt that the clients were 
delaying the test in order to miss a positive mark. This change in behavior again 
may vary the results of the predictions. However, assessors felts that if there 
were more strict guidelines in regards to the programs, such as state level laws 
and amendments, they would be more inclined to enforce the range of collection 
times. Again, having less variance between the monitoring periods will lead to 
better predictions into relapse. 
 
27	  	  
	  
 
  
5.3 Limitations of Indirect Biomarkers  
     Biomarkers are proving to be extraordinary tools in the monitoring of alcohol 
consumption, however there are limitations inherent in indirect biomarkers. 
Indirect biomarkers are solely measuring the toxic effects of alcohol on one’s 
system. The biomarkers are not direct measures of alcohol in ones system, and 
may not be representative of one’s true drinking pattern. For example, if an 
individual has one drinking binge (five drinks or more in a two hour period) in a 
two-week monitoring period, the biomarker would not show up positive. By failing 
to detect this drinking pattern, there may be inherent flaws in using indirect 
biomarkers for predicting rearrests.  
 
5.4 Future Directions  
Having information regarding who would relapse, or commit another DUI 
offense can be invaluable in regards to economic impact, as well as resource 
allocation. The biomarkers highlighted within this thesis are relatively inexpensive 
to run. Currently, the EDAC is $36 dollars to perform representing a small value 
considering the potential return on investment. Clearly, the dataset illustrates that 
individuals are abstaining or reducing their drinking throughout the monitoring 
period. This effectiveness is a giant leap in the treatment of these repeat offense 
drunk drivers.  
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Furthermore, in the overarching nature of this exercise, this research is 
attempting to demonstrate the ability to use data mining techniques on complex 
biomedical data. Much of the data, particularly biomedical data related to 
behavioral health are analyzed solely with traditional statistical techniques. These 
techniques are excellent in illustrating apriori hypothesis as well as, limited post-
hoc hypothesis. However, within complex data, patterns are inherent which may 
aid in the evaluation as well as creation of new treatment methods leveraging the 
power of computers. The research illustrates that we are on the precipitous of 
this change, and that this new research methods are providing valuable insight 
within existing biomedical data.  
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Appendix A
 
 
 
Letter to Use Ex Post Facto/Retrospective Data 
5/29/2013 
Graduate School 
University of Wisconsin-Milwaukee 
3203 N Downer Ave 
Milwaukee, Wi 53211 
 
University IRB Office:  
As Executive Director, I have given Mr. Brian Kay permission to review and use archival 
data on clients previously enrolled in our biomarker pilot program from 2008-2010. I 
have spoken with Mr. Kay and understand the scope of his research, and how he will be 
using our data. All information to be gathered will be done in a confidential, deidentified 
and in an appropriate manner. Additionally, all data collected will be reported in 
aggregate under the conditions of the projects Authorization to Disclose Information. 
Should you have any questions, please feel free to contact me.  
Sincerely,  
    
 
                        
Dr. Claudia Roska Executive Director of the Addition Resource Council  
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Appendix B  AUTHORIZATION	  AND	  RELEASE	  FOR	  	  ALCOHOL	  CONSUMPTION	  TESTING	  AND	  MONITORING	  	  	  I,	  _____________________________________,	  am	  a	  participant	  in	  the	  Addiction	  Resource	  Council’s	  (“Agency”)	  Driver	  Safety	  Program	  that	  monitors	  my	  alcohol	  consumption	  through	  the	  use	  of	  bio-­‐markers.	  By	  agreeing	  to	  participate	  in	  this	  program	  I	  hereby	  agree	  to	  the	  terms	  and	  conditions	  of	  this	  Authorization	  and	  Release	  Form	  (“Form”).	  	  
1. Consent to Alcohol Consumption Tests and Blood Draws. I hereby agree to 
undergo alcohol consumption tests (“Testing(s)”) at such intervals as established 
by the Agency to determine my level of alcohol consumption within the 14 to 21 
days preceding the Testing.  I further agree that the laboratory and Alcohol 
Detection Services, LLC (“Company”) will need accurate information and 
compliance with the testing procedures from me, in order for them to provide 
reliable test results: 
 
(a) I consent to having two vials of my blood drawn for each Testing and 
authorize the Laboratory the “Laboratory”) to run such tests on the blood 
samples as instructed by the Company for the sole purpose of conducting the 
Testing(s). 	  
(b) I authorize the Laboratory to provide the results of my blood test(s) to the 
Company and to my Primary Care Physician listed below. 
 
(c) I authorize the Company to conduct the Testing(s) using my blood test results 
provided by the laboratory and to provide the Testing results directly to the 
Agency. I understand that Company will not provide me a copy of the testing 
results and that I must seek information regarding such results directly from 
the Agency. 
 
(d) I will be financially responsible for all cost related to each blood draw, 
Laboratory test and Company testing described in (a-c) above. 
 
(e) I authorize the Agency, Laboratory, Company and Primary Care Physician to 
share and communicate with one another as necessary and appropriate for my 
monitoring and treatment under this program. 
 2.	   Primary	  Care	  Physician:	  	  Name	  of	  Physician:	  _________________________________________________________________________	  	  Address:	  __________________________________________________________________________________	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  City,	  State	  Zip	  Code:	  _________________________________________________________________________	  	  Facsimile	  Number:	  ______________________________	  Telephone	  Number:	  ___________________________	  	  3.	   List	  all	  current	  Medications	  you	  are	  taking	  (Please	  print):	  	  	   _______________________________________	   _______________________________________	  	  	   _______________________________________	   _______________________________________	  	  	   _______________________________________	   _______________________________________	  	  	   _______________________________________	   _______________________________________	  	  4.	   List	  all	  current	  Medical	  conditions	  for	  which	  you	  are	  being	  treated	  (Please	  
print):	  	  	   _______________________________________	   _______________________________________	  	  	   _______________________________________	   _______________________________________	  	  	   _______________________________________	   _______________________________________	  	  	   _______________________________________	   _______________________________________	  	  5.	   Client	  current	  contact	  information	  (Please	  print):	  	  	   Name	  (Last,	  First,	  MI)	  __________________________________________________________________	  	  	   Address:	  ____________________________________________________________________________	  	   Home	  Telephone	  Number:	  ______________________________________________________________	  	  Cell	  Phone	  Number:	  ___________________________________________________________________	  	  6.	   Authorization	  to	  Release	  Confidential	  Medical	  Information.	  I	  understand	  that	  although	  the	  Laboratory	  is	  subject	  to	  state	  confidentiality	  laws	  and	  the	  privacy	  rules	  under	  the	  Health	  Insurance	  Portability	  and	  Accountability	  Act	  of	  1996	  (“HIPAA”),	  the	  Company	  is	  not	  subject	  to	  such	  laws.	  	  Whenever	  possible,	  Company	  will	  comply	  with	  the	  privacy	  regulations	  promulgated	  pursuant	  to	  the	  Health	  Insurance	  Portability	  and	  Accountability	  Act	  of	  1996	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(“HIPAA”).	  	  Because	  the	  Company	  is	  not	  subject	  to	  HIPAA	  or	  any	  state	  confidentiality	  laws,	  I	  understand	  that	  any	  health	  information	  disclosed	  to	  the	  Company	  pursuant	  to	  this	  Form	  may	  be	  subject	  to	  redisclosure	  and	  no	  longer	  be	  protected	  by	  state	  confidentiality	  laws	  or	  HIPAA.	  I	  further	  understand	  that	  I	  have	  the	  right	  to	  revoke	  this	  authorization	  at	  any	  time	  by	  providing	  written	  notice	  of	  such	  revocation	  to	  the	  Agency	  in	  accordance	  with	  their	  policies	  and	  procedures.	  	  I	  understand	  that	  any	  revocation	  will	  not	  be	  effective	  to	  the	  extent	  that	  any	  party	  has	  already	  acted	  in	  reliance	  upon	  this	  authorization.	  I	  authorize	  and	  consent	  for	  the	  Company	  to	  provide	  the	  Testing	  results	  to	  the	  Agency	  requesting	  such	  Testing(s)	  or	  as	  otherwise	  required	  by	  law.	  I	  understand	  that	  the	  Testing	  results	  may	  impact	  my	  Driver	  Safety	  Plan.	  	  This	  authorization	  shall	  be	  in	  effect	  for	  one	  year	  following	  the	  date	  this	  Form	  is	  executed	  or	  until	  I	  complete	  my	  participation	  in	  the	  Agency	  or	  complete	  and	  am	  discharged	  form	  my	  Driver	  Safety	  Plan,	  whichever	  comes	  first.	  I	  also	  understand	  that	  failure	  to	  appear	  at	  the	  appointed	  laboratory	  to	  have	  my	  blood	  drawn	  for	  the	  purpose	  of	  obtaining	  and	  EDAC™	  result	  will	  be	  considered	  a	  refusal	  and	  reported	  as	  a	  positive	  screen	  to	  my	  attorney	  and/or	  the	  Agency.	  	  7.	   Release.	  I	  understand	  that	  the	  Company	  is	  not	  responsible	  for	  any	  erroneous	  Testing	  results	  that	  occur	  because	  of	  testing	  errors	  made	  by	  the	  Laboratory.	  	  I	  hereby	  release	  and	  forever	  discharge	  and	  hold	  harmless	  Company,	  as	  well	  as	  any	  of	  its	  managers,	  members,	  officers,	  employees,	  agents	  and	  representatives	  from	  any	  claims,	  liabilities,	  suits,	  losses,	  demands,	  obligations,	  costs	  incurred,	  expenditures,	  damages	  or	  causes	  of	  action	  of	  any	  nature	  whatsoever	  arising	  out	  of,	  related	  to,	  or	  in	  any	  way	  connected	  with	  the	  Testing,	  including	  without	  limitation	  claims,	  liabilities,	  suits,	  losses,	  demands,	  obligations,	  costs	  incurred,	  expenditures,	  damages	  or	  causes	  of	  action	  of	  any	  nature	  whatsoever	  arising	  from	  any	  investigation	  or	  personnel	  actions.	  	  8.	   General	  Acknowledgments.	  By	  signing	  below,	  I	  acknowledge	  that	  I	  have	  read	  this	  Form	  and	  understand	  the	  rights	  I	  have	  and	  the	  rights	  I	  am	  giving	  up	  by	  agreeing	  to	  the	  terms	  and	  conditions	  set	  forth	  in	  this	  Form.	  I	  also	  acknowledge	  that	  all	  of	  the	  information	  is	  true	  and	  correct	  and	  I	  have	  received	  a	  copy	  of	  this	  Form.	  	  	  SIGNATURE:	  ______________________________________________	  Date:	  ____________________________	  	  PRINT	  NAME:	  _____________________________________________	  	  AGENCY	  WITNESS:	  _________________________________________	  	  Date:	  ___________________________	  	  PRINT	  NAME:	  __________________________________________	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  C	  	  	  
	  	  	  	  
Jessica Rice 
IRB Administrator 
Institutional Review Board 
Engelmann 270 
P. O. Box 413 
Milwaukee, WI  53201-0413 
(414) 229-3182 phone 
(414) 229-6729 fax 
 
http://www.irb.uwm.edu 
ricej@uwm.edu 
 
Department of University Safety & Assurances 
 
 
New Study - Notice of IRB Exempt Status 
 
 
Date: June 17, 2013 
  
To:  Rohit Kate, PhD 
Dept:  College of Health Sciences 
 
Cc: Brian Kay 
 
IRB#: 13.429 
Title: ALCOHOL BIOMARKERS AS PREDICTIVE FACTORS OF REARREST IN HIGH 
RISK REPEAT OFFENSE DRUNK DRIVERS 
 
After review of your research protocol by the University of Wisconsin – Milwaukee Institutional 
Review Board, your protocol has been granted Exempt Status under Category 4 as governed by 
45 CFR 46.101(b). 
 
Unless specifically where the change is necessary to eliminate apparent immediate hazards to the 
subjects, any proposed changes to the protocol must be reviewed by the IRB before 
implementation. It is the principal investigator’s responsibility to adhere to the policies and 
guidelines set forth by the UWM IRB and maintain proper documentation of its records and 
promptly report to the IRB any adverse events which require reporting.   
 
It is the principal investigator’s responsibility to adhere to UWM and UW System Policies, and 
any applicable state and federal laws governing activities the principal investigator may seek to 
employ (e.g., FERPA, Radiation Safety, UWM Data Security, UW System policy on Prizes, 
Awards and Gifts, state gambling laws, etc.)  which are independent of IRB review/approval. 
 
Contact the IRB office if you have any further questions. Thank you for your cooperation and best 
wishes for a successful project 
 
Respectfully, 
 
Jessica P. Rice 
IRB Administrator 
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Appendix	  D	  	  	  
Classifier	   Percent	  	  "Re-­‐offender"	  Classified	  Correctly	  	   Percent	  "No	  Re-­‐Offense	  Classified	  Correctly	   Number	  of	  folds	  
SVM	   64%	   55%	   10	  
Neural	  
Network	   17%	   19%	   10	  
Logistic	  
Regression	   25%	   36%	   10	  
Decision	  Tree	  
(J	  48)	   0%	   0%	   10	  
Classify	  and	  
Regression	  
Tree	   0%	   0%	   10	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Appendix	  E	  	  	  	  	  	  	  	  	  	  	  0.8955	  *	  (normalized)	  Days	  btw	  	  +	  	  	  	  	  	  -­‐2.0574	  *	  (normalized)	  DUI	  	  +	  	  	  	  	  	  	  0.1849	  *	  (normalized)	  EDACS1	  	  +	  	  	  	  	  	  -­‐0.3676	  *	  (normalized)	  EDACT1	  	  +	  	  	  	  	  	  	  0.6553	  *	  (normalized)	  GGT1	  	  +	  	  	  	  	  	  -­‐0.2897	  *	  (normalized)	  CDT1	  	  +	  	  	  	  	  	  	  0.1139	  *	  (normalized)	  EDACS2	  	  +	  	  	  	  	  	  	  0.2697	  *	  (normalized)	  EDACT2	  	  +	  	  	  	  	  	  	  0.2484	  *	  (normalized)	  GGT2	  	  +	  	  	  	  	  	  -­‐1.5089	  *	  (normalized)	  CDT2	  	  +	  	  	  	  	  	  	  0.4252	  *	  (normalized)	  EDACS3	  	  +	  	  	  	  	  	  	  0.3726	  *	  (normalized)	  EDACT3	  	  +	  	  	  	  	  	  -­‐0.0899	  *	  (normalized)	  GGT3	  	  +	  	  	  	  	  	  -­‐0.0966	  *	  (normalized)	  CDT3	  	  +	  	  	  	  	  	  	  0.1686	  *	  (normalized)	  EDACS4	  	  +	  	  	  	  	  	  	  1.1438	  *	  (normalized)	  EDACT4	  	  +	  	  	  	  	  	  	  0.6142	  *	  (normalized)	  GGT4	  	  +	  	  	  	  	  	  	  0.4973	  *	  (normalized)	  CDT4	  	  +	  	  	  	  	  	  	  1.5009	  *	  (normalized)	  TLFB	  	  +	  	  	  	  	  	  	  0.0156	  *	  (normalized)	  Total	  drinks	  	  +	  	  	  	  	  	  	  0.0699	  *	  (normalized)	  mean	  drinks	  	  +	  	  	  	  	  	  -­‐0.8163	  *	  (normalized)	  drinking	  days	  	  +	  	  	  	  	  	  	  0.176	  	  *	  (normalized)	  abstinent	  days	  	  +	  	  	  	  	  	  -­‐1.049	  	  *	  (normalized)	  Gender	  	  +	  	  	  	  	  	  -­‐1.2289	  *	  (normalized)	  Age	  	  +	  	  	  	  	  	  	  0.608	  	  *	  (normalized)	  Employment=Unemployed	  	  +	  	  	  	  	  	  -­‐0.0462	  *	  (normalized)	  Employment=Part	  time	  	  +	  	  	  	  	  	  	  0.0836	  *	  (normalized)	  Employment=Fulltime	  	  +	  	  	  	  	  	  	  1.0958	  *	  (normalized)	  Employment=Retired	  	  +	  	  	  	  	  	  -­‐0.5804	  *	  (normalized)	  Employment=Laid	  off	  	  +	  	  	  	  	  	  -­‐0.5804	  *	  (normalized)	  Employment=Temp	  	  +	  	  	  	  	  	  -­‐0.5804	  *	  (normalized)	  Employment=Disabled	  	  +	  	  	  	  	  	  	  0.1079	  *	  (normalized)	  Marital=Single	  	  +	  	  	  	  	  	  -­‐0.2003	  *	  (normalized)	  Marital=Married	  	  +	  	  	  	  	  	  	  1.6348	  *	  (normalized)	  Marital=Engaged	  	  +	  	  	  	  	  	  -­‐0.5804	  *	  (normalized)	  Marital=Widowed	  	  +	  	  	  	  	  	  	  0.396	  	  *	  (normalized)	  Marital=Divorced	  	  +	  	  	  	  	  	  -­‐1.3578	  *	  (normalized)	  Marital=Separated	  	  -­‐	  	  	  	  	  	  	  1.387	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